Please provide your email address to receive an email when new articles are posted on . Percent-predicted FEV 1, sweat chloride and safety were analyzed in two phase 3 trials of vanzacaftor ...

The startups are the fourth and fifth drugmakers to file for initial stock sales since late December — the most IPO activity ...

Patients aged 6 to 11 years with cystic fibrosis receiving 24-week once-daily vanzacaftor/tezacaftor/deutivacaftor generally ...

The commitment of organizations like the Cystic Fibrosis Foundation to global research funding and access initiatives has further propelled market growth. Additionally, major pharmaceutical companies, ...

Odyssey Therapeutics and Sionna Therapeutics have filed IPO paperwork, swelling the pack of startups that will provide an ...

Its Respiratory Advisory Committee has recommended funding with high priority for children aged two to five years. The medicine is currently only funded for ages six and up Cystic Fibrosis NZ CEO Lisa ...